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Abstract A practical approach for the preparation of
(5Z ) 5-ylidene rhodanine derivatives bearing the (4,5-
dihalogeno-pyrrol-2-yl)carbamoyl fragment of dispacamide
A is reported. The new compounds were obtained in good
yields (19–88 %) by Knoevenagel condensation according
to a solution-phase microwave dielectric heating protocol
in the presence of organic bases (piperidine, TEA, and
AcONa) from a set of N -substituted rhodanines 2(a–i). The
ten synthetic products 3(a–j) have been synthesized with a
Z -geometry about their exocyclic double bond and the struc-
ture of one of these compounds (3) was confirmed by a single
X-ray diffraction analysis. The new (5Z ) 5-ylidene rhodanine
derivatives 3(a–j) were tested against eight protein kinases.
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Introduction
During the two last decades, the 5-arylidene-2-thioxo-
thiazolidine-4-ones and 5-arylidene rhodanine derivatives
have been the subject of intensive research by organic
chemists and biologists because such compounds represent
privileged scaffolds in drug discovery. A survey of recent lit-
erature showed that these compounds display a wide range of
pharmaceutical properties. For example, epalrestat I (Fig. 1)
was used in the treatment of diabetic peripheral neuropa-
thy [1] and has been evaluated as aldose reductase inhibitor
[2]. The 5-benzylidene rhodanine core (compound II) has
been shown to inhibit the pancreatic cholesterol esterase
[3] (CEase). A series of dimeric analogs based on BH3I
[4] have been developed as small-molecule Bcl-2 antago-
nists (compounds III) for apoptosis through a complete SAR
study [5]. To discover chemical probes to further under-
stand the function of human DNA polymerase λ in cancer by
high-throughput screening (HTS) using SYBR Green-based
assay [6] and three 5-arylidene-2-thioxo-thiazolidine-4-ones
(compounds IV) were identified as potent inhibitors. For
Alzheimer’s disease, compounds containing the 5-arylidene
rhodanine moiety are reported to have an inhibitory effect
(compounds V) of tau aggregation [7], amyloid polypeptide
fibril formation [8,9], regulation of cathepsin-D immuno-
reactivity (compound VI) in the senile plaques [10,11]. In
addition, rhodanine-based molecules have become a popu-
lar small-molecule family of inhibitors for numerus targets
in malaria [12,13], Hepatitis C [14], HIV infection [15,16],
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Fig. 1 Structures of some bioactive 5-arylidene rhodanine derivatives (I–VI) and leucettine L41 (VII)
Fig. 2 N -3-substituted
5-ylidene rhodanine derivatives
based on dispacamide A model
O
H
NN
H
X
X N
S
S
O
New 5-ylidene rhodanines derivatives
R
O
H
NN
H
Br
Br NH
N
NH2
O
Dispacamide A
2-amino imidazolin-4-one
platform
rhodanine
platform
obstructive pulmonary disease and asthma [17], anthrax and
botulinum [18].
Our group, during the last 10 years, has investigated the
chemical development of analogs of marine sponge alka-
loid as inhibitors of protein kinases. Protein kinases rep-
resented a class of enzymes, which catalyze protein phos-
phorylation, a key cellular regulatory mechanism that is fre-
quently deregulated in human diseases. We have recently
identified the marine sponge alkaloid leucettamine B as an
inhibitor of DYRKs/CLKs [19,20]. The synthesis of analogs
of leucettamine B named leucettines (leucettine L41 VII) and
the biological characterization of leucettines [21] showed
that this family of kinase inhibitors deserves futher opti-
mization as potential therapeutics against neurodegenera-
tive diseases such as Alzheimer’s diseases [22,23]. In par-
allel, the 2-amino imidazoline-4-one moiety present in the
marine sponge alkaloid dispacamide A (Fig. 1) [24] repre-
sented also an attractive scaffold for the search of poten-
tial new inhibitor of protein kinases. Recently, we have
developed an efficient approach to dispacamide A and its
analogs [25] in seven steps with an overall yield ranging
from 12 to 33 %. Unfortunately, the preliminary biologi-
cal screening results of these new dispacamide A deriv-
atives [26] showed moderate inhibition activities against
serine/threonine kinases. In our efforts to discover new
low molecular weight inhibitors of disease-relevant protein
kinases, we focused now our attention on the synthesis of N -
3-substituted 5-ylidene rhodanine derivatives based on dis-
pacamide A model (Fig. 2). In this context, the 2-amino-
imidazoline-4-one platform of dispacamide A was replaced
by a rhodanine platform.
In this approach, the planned retrosynthesis of these
5-ylidene rhodanine derivatives is based around the key
aldol condensation between the N -(4,5-dihalogeno pyrrol-
2-yl) carbamoyl aldehyde building-block and various 2-
thioxo-thiazolidine-4-ones. This route was envisaged to be
amenable to the design of new 5-ylidene rhodanine deriva-
tives for their preliminary screening as kinase inhibitors. Our
goal in this study is the development of a convenient, high
yielding and robust reaction protocol for the preparation of
new N -3-substituted 5-yliden-2-thioxo-thiazolidine-4-one
derivatives.
Results and discussion
The overall strategy to the target 5-ylidene N−substituted
rhodanine derivatives is outlined in Scheme 1. For this
study, we have examined the reactivity of various 2-thioxo-
thiazolidine-4-ones 2(a–i) with the N -(4,5-dihalogeno
pyrrol-2-yl) carbamoyl aldehydes 1(a,b) in Knœvenagel con-
densation under microwave dielectric heating. For the syn-
thesis of small molecules with potential biological activity,
the use of microwave irradiation is growing in importance
[27,28] because the major benefits of performing reaction
under microwave irradiation are higher product yields and
shorter reaction times as compared to reactions which run
with conventional heating (i.e., in oil bath). A key advan-
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tage of modern commercial scientific laboratory microwave
apparatus is their ability to control reaction conditions pre-
cisely, by monitoring temperature/pressure, and reaction
times.
The N -(4,5-dihalogeno pyrrol-2-yl) carbamoyl aldehyde
partners 1(a,b) were prepared in three steps according to our
previously published method [24]. Starting from commercial
readily available 2-trichloroacetyl pyrrole, a regioselective
halogenation was conducted by addition of bromine (X = Br)
or sulfuryl chloride (X = Cl) to give the corresponding C-4,
C-5 dihalogeno pyrroles (70–90 %), which were then coupled
with 3,3-diethoxy-1-aminopropane (75–88 %). The corre-
sponding N -(4,5-dihalogenopyrrol-2-yl) carbamoyl acetals
were deprotected with p-TsOH at 55 ◦C after 6 h (98 %) and
led to the aldehyde building-blocks 1(a,b) in good overall
yields (1a 60 % for X = Br; 1b 66 % for X = Cl).
For the present study, we have investigated the chemi-
cal reactivity of a series of various N -substituted rhodanines
2(a–i) for Knoevenagel condensation in the presence of alde-
hydes 1(a,b). Among these compounds, rhodanine 2a, 2-
(4-oxo-2-thioxo-thiazolidin-3-yl)acetic acid 2b and 3-amino
rhodanine 2d are commercially available. Access to 3-(4-
oxo-2-thioxo-thiazolidin-3-yl)propanoic acid 2c (Scheme 2)
could be accomplished by the reaction of β-alanine with car-
bon disulfide and bromoacetic acid in aqueous potassium
hydroxide [29]. After 3 h at room temperature, the reac-
tion mixture was acidified at pH 4 and the desired insolu-
ble compound 2c was obtained in 44 % yield (Table 1) by
simple filtration. To introduce the arylsulfonamide function-
ality on the rhodanine moiety in compound 2e, we used the
Power’s approach [14]: firstly, the formation of the arylsul-
fonyl hydrazide was accomplished by treatment of sulfonyl
chloride at 0 ◦C with hydrazine in THF followed by aqueous
work-up and, secondly, the arylsulfonyl hydrazide treated
with bis-(carbomethyl)trithiocarbonate [30,31] in water at
95 ◦C for 22 h produced 3-(arylsulfonylamino)rhodanine
2e in 41 % yield after purification by crystallization from
ethanol.
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Table 1 Results for the preparation of N -substituted rhodanines 2c, 2(e–i)
Compound Structure Yielda (%) Compound Structure Yielda (%)
2c 44 2g 98
S
N
S
O
CO2H S
N
S
O
N
O
H
O
2e 41 2h 98
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N
S
O
N
S
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OO
S N
S
O
N
O
H
2f 90 2i 84
S
N
S
O
N
O
H
S
N
S
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N
O
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a Isolated yields after purification
Next, the preparation of compounds 2(f–i) involved the
use of commercial 3-amino rhodanine 2d as starting product.
Among the conditions studied, we found that reaction of 2d
with benzoyl chloride in THF at 60 ◦C gave good conversion
to 2f (90 %) after 2 h. For compounds 2(g–i), optimal reaction
conditions were obtained only in dry toluene at 50 ◦C. After a
reaction time ranging from 8 (for 2g, h) to 23 h (for 2i) which
were monitored by thin-layer chromatography on silica gel
using dichloromethane/ethanol (9:1) as eluent, we obtained
the crystallized compounds 2(g–i) in good to high yields
(84–98 %). With the desired N -substituted rhodanines 2(a–i)
and the N -(4,5-dihalogeno pyrrol-2-yl)carbamoyl aldehydes
1(a, b) in hand, we proceeded to examine the Knoevenagel
condensation under microwave dielectric heating for the syn-
thesis of new 5-ylidene rhodanines 3(a–j) based on the dis-
pacamide A model. In literature, the condensation of an aryl
aldehyde to 2-thioxo-thiazolidine-4-one required the pres-
ence of a base such as piperidine in ethanol [32,33], piperi-
dine/AcOH in ethanol under microwave irradiation [34–37]
or with a catalytic amount of piperidinium acetate in refluxing
toluene [38], AcONa in refluxed AcOH [39,40] or concen-
trated ammonia solution in the presence of NH4Cl [41]. The
use of solventless reaction conditions has also been employed
with task specific ionic liquids (TSILs) [42,43] or with a solid
inorganic support (Al2O3 or KSF) under microwave [44]. In
this context, we decided to perform the condensation reac-
tion under microwave dielectric heating and we screened a
range of reaction parameters in order to find optimal reaction
conditions. Reaction optimization for the synthesis of com-
pounds 3(a–j) consisted of varying the reaction temperature
(70–150 ◦C), the irradiation power (50–200 W), the reaction
time (20–40 min), the nature of the solvent (EtOH, AcOH, or
AcOEt), the base (piperidine, Et3N or AcONa) and the ratio
of rhodanine 2 with the base. The reactions were conducted
in borosilicate vials of 10 mL equipped with snap caps (at
the end of the irradiation reaction time, cooling was realized
automatically by compressed air). As shown in Table 2, the
use of 0.1 equivalent of piperidine/AcOH in ethanol has been
employed for the synthesis of N -3-substituted 5-ylidene rho-
danine derivatives 3(a–c) and3f in poor (3f 19 %), moderate
(3c 46 %) to good yields (3a 88 % and 3b 82 %). In con-
trast, any effort to obtain Knoevenagel condensation adducts
from the reaction of the other N -substituted rhodanines 2
with aldehydes 1(a, b) was unsuccessful using these reaction
conditions. This implies that new specific synthetic protocols
has to be devised for the others products 3. Finally, treatment
of 1 and 2 with a stoichiometric mixture of AcONa/AcOH
(1 equivalent) during 20 min at 120–140 ◦C afforded the
compounds 3d and 3(g–j) in yields ranging from 46 to 74 %.
It is noteworthy that access to compound 3e required the
use of triethylamine (TEA) in glacial acetic acid instead of
piperidine or AcONa and the condensation reaction was con-
ducted in ethyl acetate (AcOEt). Compound 3e was synthe-
sized in 71 % yield after a reaction time of 30 min using
moderate reaction temperature (70 ◦C) and irradiation power
(50 W) in a glass vial without snap caps (or in open vessel at
atmospheric pressure).
Structures of the desired compounds 3(a–j) were sub-
stantiated by 1H, 13C NMR and HRMS analyses. In theory,
E and Z geometrical isomers around the exocyclic double
(CH=C) are possible for the N -3-substituted 5-ylidene rho-
danine derivatives 3(a–j). 1H NMR spectra of these com-
pounds 3 show only one signal for the methylene proton
(CH=) in the range of 6.82–7.20 ppm, at lower field val-
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Table 2 Results for the preparation of N -3-substituted 5-ylidene rhodanine derivatives 3(a–j) from N -substituted rhodanines 2(a–i) and 4,5-
dihalogeno-1H -pyrrole-2-carboxylic acid (3-oxopropyl)-amide 1(a, b)
Compound Structure of
compound 3
Reaction conditions used under microwavea Yieldb (%)
Reagents Solvent
reaction
Reac. temp.
(◦C)
Reac. time
(min)
Power
(W)
3a piperidine/AcOH (0.1 eq.) EtOH 150 20 200c 88
O
H
NN
H
Br
Br NH
S
S
O
3b piperidine/AcOH (0.1 eq.) EtOH 150 20 200c 82
O
H
NN
H
Cl
Cl NH
S
S
O
3c piperidine/AcOH (0.1 eq.) EtOH 110 40 −d 46
O
H
NN
H
Br
Br N
S
S
O
CO2H
3d AcONa/AcOH 1 eq. AcOH 140 20 60c 46
O
H
NN
H
Br
Br N
S
S
O
CO2H
3e Et3N /AcOH (0.1 eq.) AcOEt 70 30 50c,e 71
O
H
NN
H
Br
Br N
S
S
O
NH2
3f piperidine /AcOH (0.1 eq.) EtOH 150 20 −d 19
O
H
NN
H
Br
Br N
S
S
O
N
H
S
OO
3g AcONa /AcOH (1 eq.) AcOH 120 20 100c 52
O
H
NN
H
Br
Br N
S
S
O
N
H
O
3h AcONa /AcOH (1 eq.) AcOH 120 20 100c 74
O
H
NN
H
Br
Br N
S
S
O
N
H
O
O
3i AcONa /AcOH (1 eq.) AcOH 120 20 100c 58
O
H
NN
H
Br
Br N
S
S
O
N
H
O
3j AcONa /AcOH (1 eq.) AcOH 120 20 100c 49
O
H
NN
H
Br
Br N
S
S
O
N
H
O
a Microwave irradiation of the reaction mixture was realized in a glass tube sealed with a snap cap (closed vessel)
b Isolated yield after workup and purification by preparative chromatography (on a Combi Flash R f 200 psi, Serlabo Technologies France using
pre-packed column of silica gel 60 F 254 Merck equipped with a DAD UV/Vis 200–360 nm detector) unless indicated otherwise
c Explorer®24 (CEM France) used as microwave reactor
d Monowave®300 (Anton Paar France) used as microwave reactor
e The reaction was conducted in glass tube without snap cap (open vessel mode)
ues than those expected for the E-isomers, which strongly
indicates that the compounds have the Z -configuration. The
Z -configuration of compounds 3(a–j)was confirmed from
the 1H-coupled 13C NMR spectrum of these compounds fol-
lowed by examination of the splitting pattern and coupling
constant of the signal of the C=O group in the rhodanine sys-
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Fig. 3 Ortep diagram of
4,5-dibromo-1H -pyrrol-2-
carboxylic acid
[3-(4-oxo-2-thioxo-thiazolidin-
5-ylidene)-propyl]-amide 3a
obtained by X-ray diffraction
Table 3 Effects of compounds 3(a–j) on the catalytic activity of eight purified protein kinasesa
Compound CDK1 CDK2 CDK5/p25 GSK3α/β CK1 DYRK1A CLK1
Dispacamide A – – – >10 – >10 –
3a >10 >10 >10 – – 5.7 –
3b >10 >10 >10 >10 >10 >10 >10
3(c–j) – – – – – – –
a Compounds were tested at various concentrations on each kinase as described in “Experimental” section. IC50 values are reported in μM, –
inactive at the highest concentration tested (10 μM); >10 inhibitory but IC50 >10 μM
tem [45]. Finally, the Z -configuration and also the chemical
structure of 3 were confirmed by the single X-ray diffrac-
tion analysis of 4,5-dibromo-1H -pyrrol-2-carboxylic acid
[3-(4-oxo-2-thioxo-thiazolidin-5-ylidene)-propyl]-amide 3a
(Fig. 3).
As an initial effort to investigate their in vitro bioactivity,
the new 5-ylidene rhodanine derivatives 3(a–j) were tested
against three protein kinases relevant to Alzheimer’s disease,
CK1α/β (casein kinase 1α/β), CDK5 (cyclin-dependent
kinase 5)/p25 and GSK-3α/β glycogen synthase kinase
3α/β. All assays were run in the presence of 15 μM ATP
and appropriate protein substrates (RRKHAAIGpSAYSITA
peptide for CK1α/β, histone H1 for CDK5/p25, GS-
1 (YRRAAVPPSPSLSRHSSPHQSpEDEEE) peptide for
GSK-3α/β). IC50 values were determined from dose–
response curves and are provided in Table 3.
These results are summarized in Table 3. The unsubsti-
tuted compound 3a showed promising inhibitory activity
against DYRK1A with IC50 value in the single-digit micro-
molar range (3a: IC50 5.7 μM). Yet the other new 5-ylidene
rhodanine derivatives 3(c–j) substituted in position N -3 were
considered inactive on CDKs, GSK3α/β,CK1, CLK1 and
DYRK1A since they displayed IC50 values above 10 μM,
these results suggested that these structures cannot be accom-
modated in the ATP binding site of these protein kinases by
hydrogen bond interactions with specific amino-acids of the
ATP-binding pocket of each protein kinase.
Conclusion
In summary, the present study described a practical
approach to new 5-ylidene rhodanine derivatives 3(a–j) bear-
ing the (4,5-dihalogeno-pyrrol-2-yl)carbamoyl fragment of
dispacamide A as potential inhibitors of protein kinases for
therapeutics against neurodegenerative diseases. The key
step of this solution phase organic synthesis involved a
Knoevenagel condensation under microwave dielectric heat-
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ing from N -(4,5-dihalogeno-pyrrol-2-yl) carbamoyl aldehy-
des 1(a, b) and N -substituted rhodanines 2(a–i) partners.
This microwave-assisted condensation afforded new (5Z ) 5-
ylidene rhodanines derivatives in a stereo-controlled fashion
with yields ranging from 19 to 88 % and in high purity after
purification by preparative chromatography on silica gel.
This work should enable further biological evaluations, new
analogs though the simple synthetic process described here,
and further studies towards a complete structure–activity
relationship (SAR). These studies are on going in our lab-
oratory.
Chemistry experimental part
Melting points were determined on a Kofler melting point
apparatus and were uncorrected. Thin-layer chromatogra-
phy (TLC) was accomplished on 0.2-mm precoated plates
of silica gel 60 F-254 (Merck). Visualization was made with
ultraviolet light (254 and 365 nm) or with a fluorescence
indicator. 1H NMR spectra were recorded on BRUKER
AC 300 P (300 MHz) spectrometer, 13C NMR spectra on
BRUKER AC 300 P (75 MHz) spectrometer. Chemical shifts
are expressed in parts per million downfield from tetram-
ethylsilane as an internal standard. Data are given in the
following order: δ value, multiplicity (s, singlet; d, dou-
blet; t, triplet; q, quartet; m, multiplet; br, broad), number
of protons, coupling constants J is given in Hz. The mass
spectra (HRMS) were taken respectively on a MS/MS ZAB-
Spec Tof Micromass (EBE TOF geometry) at an ionizing
potential of 8 eV and on a VARIAN MAT 311 at an ioniz-
ing potential of 70 eV in the “Centre Régional de Mesures
Physiques de l’Ouest” (CRMPO, Rennes). Reactions under
microwave irradiations were realized in the Explorer®24
CEM microwave reactor (CEM France) and also in the
Anton Paar Monowave 300®microwave reactor (Anton Paar
France) using borosilicate glass vials of 10 mL equipped
with snap caps (at the end of the irradiation, cooling reaction
was realized by compressed air). The microwave instrument
consists of a continuous focused microwave power output
from 0 to 300 W for the Explorer®24 CEM apparatus and
from 0 to 800 W for the Anton Paar Monowave 300®ap-
paratus. All the experiments were performed using stirring
option. The target temperature was reached with a ramp of
2 min and the chosen microwave power stay constant to hold
the mixture at this temperature. The reaction temperature
is monitored using calibrated infrared sensor and the reac-
tion time included the ramp period. The microwave irradi-
ation parameters (power and temperature) were monitored
by the ChemDriver software package for the Explorer®24
CEM apparatus and by the Monowave software package for
the Anton Paar Monowave 300®reactor. Preparative chro-
matographies were realized on a Combi Flash R f 200 psi
(Serlabo Technologies France) using pre-packed column of
silica gel 60 F 254 Merck equipped with a DAD UV/Vis
200–360 nm detector. Elemental analyses were performed on
a Flash Microanalyzer EA1112 CHNS/O Thermo Electron
in the “Centre Régional de Mesures Physiques de l’Ouest”
(CRMPO, Rennes). Solvents were evaporated with a BUCHI
rotary evaporator. All reagents and solvents were purchased
from Acros, Aldrich Chimie, and Fluka France and were
used without further purification. The starting aldehydes
4,5-dibromo-1H -pyrrole-2-carboxylic acid (3-oxo-propyl)-
amide 1a and 4,5-dichloro-1H -pyrrole-2-carboxylic acid (3-
oxo-propyl)-amide 1b were synthesized according to our pre-
vious methods described in literature [19].
3-(4-Oxo-2-thioxo-thiazolidin-3-yl)-propionic acid (2c)
In a 25 mL two-necked round-bottomed flask provided
with a magnetic stirrer and condenser, β-alanine (500 mg,
5.61 mmol) was solubilized in a solution of 22 % potassium
hydroxide at room temperature. To this homogeneous solu-
tion was added carbon disulfide (0.37 mL, 6.12 mmol) drop-
wise during 10 min at 25 ◦C. After stirring over a period
of 3 h, commercial bromoacetic acid (781 mg, 5.61 mmol)
was added in small portions to the reaction mixture. The
yellowish solution was vigorously stirred at 25 ◦C during
3 h. The resulting orange solution was acidified at pH 4
with conc sulfuric acid then, stirred over a period of 16 h
and orange needles appeared in the suspension. The insol-
uble product 2c was collected by filtration and dried under
high vacuum (10−2 Torr) at 25 ◦C for 2 h. The product 2c
(503 mg, 44 % yield) was further used without purification.
Mp = 162–164 ◦C. 1H NMR (DMSO-d6) δ: 4.05 (m, 4H,
H-3, CH2); 4.22 (s, 2H, H-5′, CH2). 13C NMR (DMSO-
d6) δ: 30.57 (C-2, CH2CO); 35.90 (C-3, NCH2); 39.57 (C-
5′, CH2S); 171.04 (C-1, C=O); 174.04 (C-4′, C=O); 202.96
(C-2′, C=S). HRMS, m/z: 249.9585 found (calculated for
C6H6NO3Na2S2 [M–H+2Na]+ requires 249.9585).
N-(4-Oxo-2-thioxo-thiazolidin-3-yl)-benzenesulfonamide
(2e)
In a 25 mL two-necked round-bottomed flask provided with
a magnetic stirrer and condenser, a suspension of commer-
cial phenylsulfonyl hydrazine (500 mg, 2.9 mmol) in 3 mL of
deionized water was vigorously stirred at 95 ◦C during 2 h and
produced an homogeneous yellow solution. To this solution
was added commercial bis-(carboxymethyl)trithiocarbonate
(657 mg, 2.9 mmol). The reaction mixture was stirred at 95 ◦C
over a period of 22 h. Water was evaporated in vacuo dur-
ing 7 h and the desired insoluble compound 2e was collected
by filtration then was submitted to purification by recrys-
tallization in 3 mL of absolute ethanol. The product 2e was
obtained as white needles in 41 % yield (344 mg). Mp = 152–
154 ◦C. 1H NMR (DMSO-d6) δ: 4.75 (s, 2H, H-5′, CH2);
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8.03 (m, 2H, H-3, Ar); 8.13 (m, 1H, H-4, Ar); 8.37 (m, 2H, H-
3, Ar); 11.31 (br s, 1H, NH). 13C NMR (DMSO-d6) δ: 32.95
(C-5′, CH2S); 127.23 (C-2, Ar); 128.97 (C-3, Ar); 133.34
(C-4, Ar); 140.78 (C-1, Ar); 170.30 (C-4′, C=O); 199.40
(C-2′, C=S). HRMS, m/z: 310.9594 found (calculated for
C9H8N2O3NaS3 [M+Na]+ requires 310.9594).
N-(4-Oxo-2-thioxo-thiazolidin-3-yl)-benzamide (2f)
In a 25 mL round-bottomed flask provided with a magnetic
stirrer and condenser, a mixture of commercial 3-amino rho-
danine 2d (500 mg, 3.37 mmol) and benzoyl chloride (0.39
mL, 3.37 mmol) was stirred in 5 mL of dry tetrahydrofuran
at 60 ◦C during 2 h. The solvent of the reaction mixture was
eliminated in a rotary evaporator under reduced pressure and
the yellowish crude residue crystallized after cooling down to
room temperature. The crude solid was washed with toluene
(2×5 mL) and was collected by filtration. The desired product
2f was obtained as a yellowish powder in 90 % yield (767 mg)
and was further used without purification. Mp = 196–198 ◦C.
1H NMR (DMSO-d6) δ: 4.53 (s, 2H, H-5′, CH2); 7.56 (m,
2H, H-3, Ar); 7.66 (m, 1H, H-4, Ar); 7.93 (m, 2H, H-2, Ar);
11.56 (br s, 1H, NH). 13C NMR (DMSO-d6) δ: 33.43 (C-5′,
CH2S); 127.75 (C-2, Ar); 128.72 (C-3, Ar); 130.90 (C-1, Ar);
132.76 (C-4, Ar); 164.44 (NHC=O); 170.42 (C-4′, C=O);
200.14 (C-2′, C=S). HRMS, m/z: 274.9927 found (calcu-
lated for C10H8N2O2NaS2 [M+Na]+ requires 274.9925).
4-Methoxy-N-(4-oxo-2-thioxo-thiazolidin-3-yl)-benzamide
(2g)
In a 25 mL round-bottomed flask provided with a magnetic
stirrer and condenser, a mixture of commercial 3-amino rho-
danine 2d (300 mg, 2.02 mmol) and p−methoxybenzoyl
chloride (345 mg, 2.02 mmol) was dispersed in 3 mL of
dry toluene. The reaction mixture was heated at 50 ◦C under
vigorous magnetic stirring and the reaction was monitored
by TLC on silica plates using dichloromethane/ethanol (9:1)
as eluent (2g R f 0.8). After 8 h, the solvent of the reac-
tion mixture was eliminated in a rotary evaporator under
reduced pressure and the crude oil was dried under high vac-
uum (10−2 Torr) at 25 ◦C for 3 h. The crude oil crystal-
lized after standing at room temperature. The desired prod-
uct 2g was obtained as yellowish powder in 98 % yield (570
mg) and was further used without purification. Mp = 190–
192 ◦C. 1H NMR (DMSO-d6) δ: 3.84 (s, 3H, CH3O); 4.51
(s, 2H, H-5′, CH2S); 7.08 (d, 2H, J = 8.9 Hz, H-3, Ar); 7.92
(d, 2H, J = 8.9 Hz, H-2, Ar); 11.39 (br s, 1H, NH). 13C
NMR (DMSO-d6) δ: 33.34 (C-5′, CH2S); 55.48 (CH3O);
113.95 (C-3, Ar); 122.96 (C-1, Ar); 129.79 (C-2, Ar); 162.67
(C-4, Ar); 163.79 (NHC=O); 170.51 (C-4′, C=O); 200.29
(C-2′, C=S). HRMS, m/z: 305.0031 found (calculated for
C11H10N2O3NaS2 [M+Na]+ requires 305.0030).
N-(4-Oxo-2-thioxo-thiazolidin-3-yl)-2-phenyl-acetamide
(2h)
In a 25 mL round-bottomed flask provided with a magnetic
stirrer and condenser, a mixture of commercial 3-amino rho-
danine 2d (300 mg, 2.02 mmol) and phenylacetyl chloride
(0.27 mL, 2.02 mmol) was dispersed in 3 mL of dry toluene.
The reaction mixture was heated at 50 ◦C under vigorous
magnetic stirring and the reaction was monitored by TLC on
silica plates using dichloromethane/ethanol (9:1) as eluent
(2h R f 0.75). After 8 h, the solvent of the reaction mixture
was eliminated in a rotary evaporator under reduced pres-
sure and the crude product was dried under high vacuum
(10−2 Torr) at 25 ◦C for 3 h. The desired product 2h was
obtained as yellowish powder in 98 % yield (538 mg) and
was further used without purification. Mp = 172–174 ◦C.
1H NMR (DMSO-d6) δ: 3.66 (s, 2H, CH2); 4.40–4.41 (br
s, 2H, H-5′, CH2S); 7.31–7.32 (m, 5H, H-2, H-3, H-4, Ar);
11.41 (br s, 1H, NH). 13C NMR (DMSO-d6) δ: 33.38 (C-
5′, CH2S); 126.52 (C-4, Ar); 128.19 (C-3, Ar); 129.11 (C-2,
Ar); 134.65 (C-1, Ar); 168.39 (NHC=O); 170.18 (C-4′C=O);
199.99 (C-2′, C=S). HRMS, m/z: 289.0082 found (calcu-
lated for C11H10N2O2NaS2 [M+Na]+ requires 289.0081).
N-(4-Oxo-2-thioxo-thiazolidin-3-yl)-3-phenyl-
propionamide (2i)
In a 25 mL round-bottomed flask provided with a magnetic
stirrer and condenser, a mixture of commercial 3-amino rho-
danine 2d (50 mg, 0.34 mmol) and 2-phenylpropionyl chlo-
ride (50μL, 0.34 mmol) was dispersed in 1 mL of dry toluene.
The reaction mixture was heated at 50 ◦C under vigorous
magnetic stirring and the reaction was monitored by TLC on
silica plates using dichloromethane/ethanol (9:1) as eluent
(2i R f 0.75). After 23 h, the solvent of the reaction mixture
was eliminated in a rotary evaporator under reduced pres-
sure. The crude residue was dissolved in dichloromethane
(15 mL) then, this organic layer was washed with 4 mL of
saturated hydrogen carbonate NaHCO3 and was dried over
MgSO4. After filtration, the solvent of the filtrate was elim-
inated in vacuo and the crude residue was dried under high
vacuum (10−2 Torr) at 25 ◦C for 1 h. The desired product
2i was obtained as orange powder in 84 % yield (80 mg)
and was further used without purification. Mp = 190–192 ◦C
.
1H NMR (DMSO-d6) δ: 2.67 (dd, 2H, J = 6.3, 8.3 Hz,
2H, CH2Ar); 2.95 (m, 2H, CH2CO); 4.47–4.48 (br s, 1H,
H-5′, CH2S); 7.32–7.35 (m, 5H, H-2, H-3, H-4, Ar); 11.05
(br s, 1H, NH). 13C NMR (DMSO-d6) δ: 30.41 (CH2Ar);
33.32 (CH2CO); 34.49 (C-5′, CH2S); 126.02–128.27 (C-2,
C-3, C-4, Ar); 140.53 (C-1, Ar); 169.79 (NHC=O); 170.24
(C-4′, C=O); 200.03 (C-2′, C=S). HRMS, m/z: 303.0239
found (calculated for C12H12N2O2NaS2 [M+Na]+ requires
303.0238).
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Standard procedure for the preparation of 4,5-dihalogeno-
1H-pyrrol-2-carboxylic acid [3-(4-oxo-2-thioxo-
thiazolidin-5-ylidene) -propyl]-amide 3(a, b)
In a 10 mL glass tube were placed successively 4,5-
dihalogeno-1H -pyrrole-2-carboxylic acid (3-oxo-propyl)-
amide 1(a, b) (3.09 mmol), commercial rhodanine 2a (3.09
mmol, 1 equiv.), piperidine (0.31 mmol, 0.1 equiv.) and
glacial acetic acid (0.31 mmol, 0.1 equiv.) in 12 mL of
absolute ethanol. The glass tube was sealed with a snap cap
and placed in the Explorer®24 CEM microwave cavity (P
= 300 W). The mixture was irradiated at 150 ◦C (with a
power of 200 W) for 20 min under vigorous magnetic stir-
ring. After microwave dielectric heating, the crude reaction
mixture was allowed to cool down at room temperature and
the volatile compounds of the reaction mixture were elim-
inated in a rotary evaporator under reduced pressure. The
crude residue was submitted to purification by preparative
chromatography (Combi Flash R f 200 psi apparatus, detec-
tor UV 254 nm) on pre-packed column of silica gel 60F
254 Merck using dichloromethane/ethanol (9:1) as eluent.
Pooling and evaporation of the solvents in vacuo gave the
expected compounds 3(a, b) which, were dried under high
vacuum (10−2 Torr) at 25 ◦C for 1 h.
4,5-Dibromo-1H-pyrrol-2-carboxylic acid [3-(4-oxo-2-
thioxo-thiazolidin-5-ylidene)-propyl]-amide (3a)
Orange powder. R f = 0.83. Yield = 88 %. Mp = 156 ◦C
(decomposition). 1H NMR (DMSO-d6) δ: 2.41 (m, 2H,
CH2CH=); 3.41 (m, 2H, NHCH2); 6.81 (t, 1H, J = 7.6 Hz,
=CH); 6.87 (d, 1H, J = 2.3 Hz, H-3, =CH, Ar); 8.31 (t, 1H,
J = 6.0 Hz, NHCO); 12.71 (br s, 1H, H-1, NH, Ar); 13.60 (br
s, 1H, H-3′, NH). 13C NMR (DMSO-d6) δ: 32.27 (CH2CH=);
36.79 (NHCH2); 97.79 (C-4, =CBr, Ar); 104.69 (C-4′, C=O);
112.59 (C-3, =CH, Ar); 124.74 (C-5′, C=CH); 127.88 (C-5,
=CBr, Ar); 130.36 (C-2, Ar); 135.02 (=CH); 159.00 (NH-
C=O); 167.49 (C-4′, C=O); 195.95 (C-2′, C=S). HRMS,
m/z: 459.8403 found (calculated for C11H9N3O792 Br2NaS2
[M+Na]+ requires 459.8401).
4,5-Dichloro-1H-pyrrol-2-carboxylic acid [3-(4-oxo-2-
thioxo-thiazolidin-5-ylidene)-propyl]-amide (3b)
Orange powder. R f = 0.79. Yield = 82 %. Mp = 180 ◦C
(decomposition). 1H NMR (DMSO-d6) δ: 2.40 (q, 2H, J =
6.5 Hz, CH2CH=); 3.43 (q, 2H, J = 6.5 Hz, NHCH2); 6.82
(m, 1H, =CH); 6.84 (s, 1H, H-3, =CH, Ar); 8.34 (t, 1H, J =
5.8 Hz, NHCO); 12.74 (br s, 1H, NH, Ar); 13.58 (br s, 1H, H-
3′, NH). 13C NMR (DMSO-d6) δ: 32.26 (CH2CH=); 36.80
(NHCH2); 107.92 (C-4, =CCl, Ar); 109.65 (C-3, =CH, Ar);
114.94 (C-4′, C=O); 124.61 (C-5, =CCl, Ar); 124.74 (C-
5′, C=CH; 130.38 (C-2, Ar); 134.96 (=CH); 159.12 (NH-
C=O); 167.48 (C-4′, C=O); 195.94 (C-2′, C=S). HRMS,
m/z: 371.9411 found (calculated for C11H9N3O352 Cl2NaS2
[M+Na]+ requires 371.9411).
(5-{3-[(4,5-Dibromo-1H-pyrrol-2-carbonyl)-amino]-
propylidene} -4-oxo-2-thioxo–thiazolidin-3-yl)-acetic acid
(3c)
In a 10 mL glass tube were placed successively 4,5-dibromo-
1H -pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (200
mg, 0.62 mmol), commercial 2-(4-oxo-2-thioxo-thiazolidin-
3-yl)-acetic acid 2b (118 mg, 0.62 mmol, 1 equiv.), piperi-
dine (6 μL, 0.062 mmol, 0.1 equiv.), glacial acetic acid (4
μL, 0.062 mmol, 0.1 equiv.) in 2.5 mL of absolute ethanol.
The glass tube was sealed with a snap cap and placed in the
Monowave®200 Anton-Paar microwave cavity (P = 800 W).
The mixture was irradiated at 110 ◦C for 40 min under vig-
orous magnetic stirring. After microwave dielectric heating,
the crude reaction mixture was allowed to cool down at room
temperature and the volatile compounds of the reaction mix-
ture were eliminated in a rotary evaporator under reduced
pressure. The crude residue was submitted to purification
by preparative chromatography (Combi Flash R f 200 psi
apparatus, detector UV 254 nm) on pre-packed column of
silica gel 60F 254 Merck using dichloromethane/methanol
(9:1) as eluent (3c: R f 0.10). Pooling and evaporation of
the solvents in vacuo gave the desired compound 3c which,
was dried under high vacuum (10−2 Torr) at 25 ◦C for 1 h.
3c was obtained as yellow powder in 46 % yield (140 mg).
Mp = 210–212 ◦C. 1H NMR (DMSO-d6) δ: 2.50 (m, 2H,
CH2CH=); 3.42 (m, 2H, NHCH2); 4.63 (s, 2H, CH2CO);
6.87 (s, 1H, =C-H, Ar); 7.07 (t, 1H, J = 7.5 Hz, =CH); 8.35
(t, 1H, J = 5.5 Hz, NHCO); 12.71 (br s, 1H, NH). 13C NMR
(DMSO-d6) δ: 30.64 (CH2CH=); 36.79 (NHCH2); 44.81
(CH2CO); 97.77 (C-4, =CBr, Ar); 104.48 (C-5′, C=CH);
112.49 (C-3, =CH, Ar); 126.72 (C-5, =CBr, Ar); 127.88 (C-
2, Ar); 137.84 (C=CH); 159.05 (NH-C=O); 164.55 (C-4′,
C=O); 167.10 (C=O, CO2H); 193.66 (C-2′, C=S). HRMS,
m/z: 517.8448 found (calculated for C13H11N3O794 Br2NaS2
[M+Na]+ requires 517.8455).
(5-{3-[(4,5-Dibromo-1H-pyrrol-2-carbonyl)-amino]-
propylidene} -4-oxo-2-thioxo–thiazolidin-3-yl)-propionic
acid (3d)
In a 10 mL glass tube were placed successively 4,5-dibromo-
1H -pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (79
mg, 0.24 mmol), 3-(4-oxo-2-thioxo-thiazolidin-3-yl)-
propionic acid 2c (50 mg, 0.24 mmol, 1 equiv.), commercial
sodium acetate AcONa (20 mg, 0.24 mmol, 1 equiv.), and
glacial acetic acid (90 μL, 1.6 mmol, 6.58 equiv.). The glass
tube was sealed with a snap cap and placed in the Explor-
er®24 CEM microwave cavity (P = 300 W). The mixture
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was irradiated at 140 ◦C (with a power of 60 W) for 20 min
under vigorous magnetic stirring. After microwave dielec-
tric heating, the crude reaction mixture was allowed to cool
down at room temperature and to the oily crude reaction
mixture was added 1 mL of deionized water. After triturat-
ing, the insoluble product 3d was collected by filtration and
was submitted to purification by preparative chromatography
(Combi Flash R f 200 psi apparatus, detector UV 254 nm)
on pre-packed column of silica gel 60F 254 Merck using
dichloromethane/ethanol (9:1) as eluent (3d R f 0.49). Pool-
ing and evaporation of the solvents in vacuo gave the desired
compound 3d which, was dried under high vacuum (10−2
Torr) at 25 ◦C for 1 h. 3d was obtained as yellowish nee-
dles in 46 % yield (58 mg). Mp = 90 ◦C (decomposition).
1H NMR (DMSO-d6) δ: 2.45 (m, 2H, CH2CH=); 2.56 (m,
2H, CH2CO); 3.41 (m, 2H, NHCH2); 4.15 (t, 2H, J = 7.8
Hz, 2H, NCH2); 6.89 (s, 1H, H-3, =C-H, Ar); 7.01 (t, 1H,
J = 7.5 Hz, C=CH); 8.32 (t, 1H, J = 5.5 Hz, 1H, NHCO);
12.72 (br s, 1H, H-1, NH, Ar). 13C NMR (DMSO-d6) δ:
30.70 (CH2CH=); 32.23 (CH2CO); 36.82 (NCH2); 97.80
(C-4, =CBr, Ar); 104.72 (C-5, =CBr, Ar); 112.60 (C-3, =CH,
Ar); 127.17 (C-5′, C=CH); 127.87 (C-2, Ar); 136.61 (CH=);
159.04 (NH-C=O); 164.86 (C-4′, C=O); 171.67 (CO2H);
193.65 (C-2′, C=S). HRMS, m/z: 507.8636 found (calcu-
lated for C14H12N3O794 Br2S2 [M-H]− requires 507.8636).
4,5-Dibromo-1H-pyrrol-2-carboxylic acid [3-(3-amino-4-
oxo- 2-thioxo-thiazolidin-5-ylidene)-propyl]-amide (3e)
In a 10 mL glass tube were placed successively 4,5-dibromo-
1H -pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (100
mg, 0.31 mmol), commercial 3-amino rhodanine 2d (46
mg, 0.31 mmol, 1 equiv.), dry triethylamine Et3N (4 μL,
0.031 mmol, 0.1 equiv.), glacial acetic acid AcOH (2 μL,
0.031 mmol, 0.1 equiv.) in 1 mL of ethyl acetate AcOEt.
The glass tube was placed (open vessel) in the Explorer®24
CEM microwave cavity (P = 300 W) and the mixture was
irradiated at 70 ◦C (with a power of 50 W) for 30 min
under vigorous magnetic stirring. After microwave dielec-
tric heating, the crude reaction mixture was allowed to cool
down at room temperature and to the crude reaction mix-
ture was added 5 mL of cyclohexane. This heterogeneous
mixture in the tube was submitted to ultrasound in a Bran-
son 1510 apparatus at 25 ◦C during 30 min. The yellow-
ish desired compound 3e was collected by filtration, washed
with Et2O (2 × 5 mL) and was purified by preparative chro-
matography (Combi Flash R f 200 psi apparatus, detector
UV 254 nm) on pre-packed column of silica gel 60F 254
Merck using dichloromethane/methanol (9:1) as eluent (3e
R f 0.69). Pooling and evaporation of the solvents in vacuo
gave the desired compound 3e which, was dried under high
vacuum (10−2 Torr) at 25 ◦C for 1 h. 3e was obtained
as a yellowish powder in 71 % yield (100 mg). 1H NMR
(DMSO-d6) δ: 2.45 (m, 2H, CH2CH=); 3.41 (m, 2H, NCH2);
5.99 (m, 1H, C=CH); 6.95 (s, 1H, H-3, Ar); 8.28 (m, 1H,
NH-CO); 12.79 (br s, 1H, NH, Ar). HRMS, m/z: 452.8693
found (calculated for C11H11N4O792 Br2S2 [M+H]+ requires
452.8690).
4,5-Dibromo-1H-pyrrol-2-carboxylic acid [3-(3-benz-
enesulfonylamino-4-oxo-2-thioxo-thiazolidin-5-ylidene)-
propyl]-amide (3f)
In a 10 mL glass tube were placed successively 4,5-dibromo-
1H -pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (100
mg, 0.31 mmol), N-(4-oxo-2-thioxo-thiazolidin-3-yl)-
benzenesulfonamide 2e (89 mg, 0.31 mmol, 1 equiv.), piperi-
dine (3 μL, 0.031 mmol, 0.1 equiv.), glacial acetic acid (2
μL, 0.031 mmol, 0.1 equiv.) in 1.2 mL of absolute ethanol.
The glass tube was sealed with a snap cap and placed in the
Monowave®200 Anton-Paar microwave cavity (P = 800 W).
The mixture was irradiated at 150 ◦C for 20 min under vig-
orous magnetic stirring. After microwave dielectric heating,
the crude reaction mixture was allowed to cool down at room
temperature and the volatile compounds of the reaction mix-
ture were eliminated in a rotary evaporator under reduced
pressure. To the black crude residue was added Et20 (5 mL)
and after triturating, the insoluble compound 3f was collected
by filtration. Then, 3f was submitted to purification by prepar-
ative chromatography (Combi Flash R f 200 psi apparatus,
detector UV 254 nm) on pre-packed column of silica gel 60F
254 Merck using dichloromethane/methanol (9:1) as eluent
(3f R f 0.69). Pooling and evaporation of the solvents in vacuo
gave the desired compound 3f which, was dried under high
vacuum (10−2 Torr) at 25 ◦C for 1 h. 3f was obtained as an
orange powder in 19 % yield (35 mg). Mp = 2424–226 ◦C.
1H NMR (DMSO-d6) δ: 2.45 (m, 2H, CH2CH=); 3.42 (m,
2H, NCH2); 6.87 (d, 1H, J = 2.7 Hz, =CH, Ar); 7.07 (t,
1H, J = 7.6 Hz, =CH); 7.56 (m, 2H, H-3′′, Ar); 7.67 (m,
1H, H-4′′, Ar); 7.80 (m, 2H, H-2′′, Ar); 8.34 (t, 1H, J =
5.9 Hz, NHCO); 11.51 (br s, 1H, NHSO2); 12.71 (br s, 1H,
NHPyr). 13C NMR (DMSO-d6) δ: 31.77 (CH2CH=); 36.66
(NCH2); 97.79 (C-4, =CBr, Ar); 104.74 (C-5, =CBr, Ar);
11260 (C-3, =CH, Ar); 123.41 (C-5′, C=CH); 127.22 (C-2′′,
Ar); 127.87 (C-2, =C-H, Ar); 129.07 (C-3′′, Ar); 133.48 (C-
4′′, Ar); 138.92 (C=CH); 140.59 (C-1′′, Ar); 159.05 (NH-
C=O); 161.73 (C-4′, C=O); 190.37 (C-2′, C=S). HRMS,
m/z: 614.8438 found (calculated for C17H14N4O794 Br2NaS2
[M+Na]+ requires 614.8442).
Standard procedure for the preparation of 4,5-dibromo-1H-
pyrrol-2-carboxylic acid [3-(3-substituted amino-4-oxo-2-
thioxo-thiazolidin-5-ylidene)-propyl]-amide (3g) and 3(i, j).
In a 10 mL glass tube were placed successively 4,5-dibromo-
1H -pyrrole-2-carboxylic acid (3-oxo-propyl)-amide 1a (52–
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122 mg, 0.16–0.38 mmol), N-acyl rhodanine 2(f–i) (45–100
mg, 0.16–0.38 mmol, 1 equiv.), commercial sodium acetate
AcONa (14–31 mg, 0.16–0.38 mmol, 1 equiv.), and glacial
acetic acid (61–140 μL, 1.06–2.47 mmol, 6.58 equiv.). The
glass tube was sealed with a snap-cap and placed in the
Explorer®24 CEM microwave cavity (P = 300 W). The mix-
ture was irradiated at 120 ◦C (with a power of 100 W) for
20 min under vigorous magnetic stirring. After microwave
dielectric heating, the crude reaction mixture was allowed
to cool down at room temperature and deionized water (2
mL) was added to the brown crude reaction mixture. The
resulting suspension was submitted to ultrasound in a Bran-
son 1510 apparatus at 25 ◦C during 30 min and the beige
insoluble product 3 was collected by filtration. Then, com-
pound 3 was triturated in 5 mL of Et2O for compounds 3g
and 3(i, j) or in 5 mL of dichloromethane for compound
3h* and again was collected by filtration. The crude prod-
ucts 3g and 3(i, j) were purified by preparative chromatogra-
phy (Combi Flash R f 200 psi apparatus, detector UV 254
nm) on pre-packed column of silica gel 60F 254 Merck
using dichloromethane/methanol (9:1) as eluent. Pooling and
evaporation of the solvents it in vacuo gave the expected
compound 3g and 3(i, j) and were dried under high vac-
uum (10−2 Torr) at 25 ◦C during 1 h. (*) The compound
3h was purified by recrystallization in dichloromethane
CH2Cl2.
4,5-Dibromo-1H-pyrrol-2-carboxylic acid [3-(3-benz-
oylamino-4-oxo-2-thioxo-thiazolidin-5-ylidene)-propyl]-
amide (3g)
Compound 3g (R f 0.69) was prepared in 52 % yield (90
mg) from 4,5-dibromo-1H -pyrrole-2-carboxylic acid (3-
oxo-propyl)-amide 1a (100 mg, 0.31 mmol), N -(4-oxo-2-
thioxo-thiazolidin-3-yl)-benzamide 2f (78 mg, 0.31 mmol),
sodium acetate AcONa (25 mg, 0.31 mmol) in glacial acetic
acid (120 μL, 2 mmol, 6.58 equiv.) according to the stan-
dard procedure. Mp = 242–244 ◦C. 1H NMR (DMSO-d6) δ:
2.50 (m, 2H, CH2CH=); 3.33 (m, 2H, NCH2); 6.89 (d, 1H,
J = 2.7 Hz, =CH, Ar); 7.20 (t, 1H, J = 7.6Hz, =CH);
7.57 (m, 2H, H-3′′, Ar); 7.67 (m, 1H, H-4′′, Ar); 7.94 (m,
2H, H-2′′, Ar); 8.39 (t, 1H, J = 6.1 Hz, NHCO); 11.72
(br s, 1H, NNHCO); 12.74 (br s, 1H, NH, Ar). 13C NMR
(DMSO-d6) δ: 31.98 (CH2CH=); 36.75 (NCH2); 97.80 (C-
4, =CBr, Ar); 104.76 (C-5, =CBr, Ar); 112.61 (C-3, =CH,
Ar); 123.84 (C-5′, =C); 127.73 (C-2′′, Ar); 127.88 (C-2,
=C-CO, Ar); 128.79 (C-3′′, Ar); 130.66 (C-1′′, Ar); 132.89
(=C); 139.36 (C-4′′, Ar); 159.08 (NH-C=O); 161.70 (C-
4′, C=O); 164.43 (NNHC=O); 191.14 (C-2′, C=S). HRMS,
m/z: 578.8774 found (calculated for C18H14N4O794 Br2NaS2
[M+Na]+ requires 578.8772).
4,5-Dibromo-1H-pyrrol-2-carboxylic acid {3-[3-(4-
methoxy-benzoylamino)-4-oxo-2-thioxo-thiazolidin-5-
ylidene]-propyl}-amide (3h)
Compound 3h was prepared in 74 % yield (154 mg) from
4,5-dibromo-1H -pyrrole-2-carboxylic acid (3-oxo-propyl)-
amide 1a (115 mg, 0.35 mmol), 4-methoxy-N -(4-oxo-2-
thioxo-thiazolidin-3-yl)-benzamide 2g (100 mg, 0.35 mmol),
sodium acetate AcONa (29 mg, 0.35 mmol) in glacial
acetic acid (130 μL, 2.33 mmol, 6.58 equiv.) according
to the standard procedure. Mp = 190 ◦C(decomposition).
1H NMR (DMSO-d6) δ: 2.53 (m, 2H, CH2CH=); 3.45
(m, 2H, NCH2); 3.84 (s, 3H, CH3O); 6.89 (d, 1H, J =
2.6 HZ, H-3, =CH, Ar); 7.09 (m, 2H, H-3′′, Ar); 7.18
(t, 1H, J = 7.7 Hz, C=CH); 7.91 (m, 2H, H-2′′, Ar);
8.38 (t, 1H, J = 5.5 Hz, 1H, NHCO); 11.53 (s, 1H,
NNHCO); 12.73 (br s, 1H, NH, Ar). 13C NMR (DMSO-
d6)δ: 31.95 (CH2CH=); 36.74 (NCH2); 55.49 (CH3O);
97.81 (C-4, =CBr, Ar); 104.76 (C-5, =CBr, Ar); 112.60
(C-3, =CH, Ar); 114.03 (C-3′′, Ar); 114.82 (C-3′′, Ar);
122.70 (C-5′, =C); 123.90 (C-2, =C-CO, Ar); 127.81 (C-
2′′, Ar); 129.80 (C-2′′, Ar); 139.21 (CH=); 159.09 (C-1′′,
Ar); 160.55 (C-4′′, Ar); 162.77 (NH-C=O); 163.84 (C-4′,
C=O); 166.31 (NNHC=O); 196.11 (C-2′, C=S). HRMS,
m/z: 608.8875 found (calculated for C20H20N4O795 Br2NaS2
[M+Na]+ requires 608.8874).
4,5-Dibromo-1H-pyrrol-2-carboxylic acid [3-(4-oxo-3-
phenylacetylamino-2-thioxo-thiazolidin-5-ylidene)-propyl]-
amide (3i)
Compound 3i (R f 0.71) was prepared in 58 % yield (126
mg) from 4,5-dibromo-1H -pyrrole-2-carboxylic acid (3-
oxo-propyl)-amide 1a (122 mg, 0.38 mmol), N -(4-oxo-
2-thioxo-thiazolidin-3-yl)-2-phenyl-acetamide 2h (100 mg,
0.38 mmol), sodium acetate AcONa (31 mg, 0.38 mmol) in
glacial acetic acid (140 μL, 2.47 mmol, 6.58 equiv.) accord-
ing to the standard procedure. Mp = 100 ◦C (decompo-
sition). 1H NMR (DMSO-d6) δ: 2.53 (m, 2H, CH2CH=);
3.43 (m, 2H, NCH2); 3.66 (s, 2H, CH2CONH); 6.87 (d,
1H, J = 2.7 Hz, =CH, Ar); 7.12 (t, 1H, J = 7.6 Hz,
C=CH); 7.29–7.33 (m, 5H, H-2′′, H-3′′, H-4′′, Ar); 8.36
(t, 1H, J = 5.9 Hz, NHCO); 11.36 (s, 1H, NNHCO);
12.71 (br s, 1H, NH, Ar). 13C NMR (DMSO-d6) δ: 28.98
(CH2CH=); 31.89 (NHCOCH2); 36.74 (NCH2); 97.81 (C-
4, =CBr, Ar); 104.74 (C-5′, C=CH); 122.62 (C-3, =CH,
Ar); 123.98 (C-5, =CBr, Ar); 126.72 (C-4′′, Ar); 127.87
(=C-CO, Ar); 128.26 (C-3′′, Ar); 129.11 (C-2′′, Ar); 134.53
(C-1′′, Ar); 138.81 (C=CH); 159.08 (NH-C=O); 161.53 (C-
4′, C=O); 168.53 (NNHC=O); 190.99 (C-2′, C=S). HRMS,
m/z: 592.8927 found (calculated for C19H16N4O793 Br2NaS2
[M+Na]+ requires 592.8928).
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4,5-Dibromo-1H-pyrrol-2-carboxylic acid {3-[4-oxo-3-
(3-phenyl-propionylamino)-2-thioxo-thiazolidin-5-ylidene]-
propyl}-amide (3j)
Compound 3j (R f 0.77) was prepared in 49 % yield (46
mg) from 4,5-dibromo-1H -pyrrole-2-carboxylic acid (3-
oxo-propyl)-amide 1a (52 mg, 0.16 mmol), N -(4-oxo-2-
thioxo-thiazolidin-3-yl)-3-phenyl-propionamide 2i (45 mg,
0.16 mmol), sodium acetate AcONa (14 mg, 0.16 mmol) in
glacial acetic acid (61 μL, 1.06 mmol, 6.58 equiv.) accord-
ing to the standard procedure. Mp = 100 ◦C (decomposi-
tion). 1H NMR (DMSO-d6) δ: 2.62 (m, 2H, CH2CO); 2.88
(m, 2H, CH2Ar); 3.43 (m, 2H, NCH2); 6.88 (d, 1H, J =
2.5 Hz, =CH, Ar); 7.13 (t, 1H, J = 7.6 Hz, C=CH); 7.23-
7.31 (m, 5H, H-2′′, H-3′′, H-4′′, Ar); 8.36 (t, 1H, J = 5.9
Hz, NHCO); 11.15 (s, 1H, NNHCO); 12.72 (br s, 1H, H-
1, NH, Ar). 13C NMR (DMSO-d6) δ: 30.36 (CH2CH=);
31.87 (CH2Ar); 34.45 (CH2CO); 36.75 (NHCH2); 97.79 (C-
4, =CBr, Ar); 104.74 (C-5, =CBr, Ar); 112.60 (C-3, =CH,
Ar); 123.99 (C-5′, C=CH); 126.04 (C-4′′, Ar); 127.87 (C-2,
=CCO, Ar); 128.23 (C-2′′, Ar); 128.28 (C-3′′, Ar); 138.73
(=CH); 140.45 (C-1′′, Ar); 159.07 (NH-C=O); 161.58 (C-
4′, C=O); 169.91 (NNHC=O); 191.02 (C-2′, C=S). HRMS,
m/z: 606.9084 found (calculated for C20H18N4O793 Br2NaS2
[M+Na]+ requires 606.9085).
X-ray crystallographic data for 4,5-dibromo-1H-
pyrrol-2-carboxylic acid [3-(4-oxo-2-thioxo-
thiazolidin-5-ylidene)-propyl]-amide (3a)
(2(C11 H9 Br2 N3 O2 S2)); M = 878.3. APEXII, Bruker-
AXS diffractometer, Mo-Kα radiation (λ = 0.71073 Å),
T = 150(2) K; triclinic P-1 (I.T.#2), a = 7.0648(6), b =
14.9877(13), c = 17.6708(13)Å, α = 75.216(3), β =
87.475(3), γ = 78.233(3)◦, V = 1771.1(3) Å3, Z = 2, d =
1.647 g cm−3, μ = 4.815 mm−1. The structure was solved
by direct methods using the SIR97 program [46], and then
refined with full-matrix least-square methods based on F2
(SHELXL-97) [47] with the aid of the WINGX [48]program.
The contribution of the disordered solvents to the calculated
structure factors was estimated following the BYPASS algo-
rithm [49], implemented as the SQUEEZE option in PLATON
[50]. A new data set, free of solvent contribution, was then
used in the final refinement. All non-hydrogen atoms were
refined with anisotropic atomic displacement parameters. H
atoms were finally included in their calculated positions. A
final refinement on F2 with 8064 unique intensities and 361
parameters converged at ωR(F2) = 0.2134(R(F) = 0.0795)
for 2888 observed reflections with I > 2σ(I). Crystallo-
graphic data for the structure of 3a in this paper have been
deposited in the Cambridge Crystallographic Data Centre as
supplementary publication number CCDC 938832. Copies
of the data can be obtained, free of charge, on application
to CCDC, 12 Union Road, Cambridge CB21EZ, UK [fax:
+44-0-1223-336033 or e-mail:deposit@ccdc.cam.ac.uk].
Biochemistry part
Protein kinase assay buffers
Buffer A 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 25 mM
Tris–HCl pH 7.5, 50μg heparin/mL. Buffer B 50 mM MgCl2,
90 mM NaCl, 30 mM Tris–HCl pH 7.4.
Kinase preparations and assays
Kinase activities for each enzyme were assayed in buffer A
or B, with their corresponding substrates, in the presence
of 15 μM ATP in a final volume of 30 μL. After 30-min
incubation at 30 ◦C, the reaction was stopped by harvest-
ing, using a FilterMate harvester (Packard), onto P81 phos-
phocellulose papers (GE Healthcare) which were washed in
1 % phosphoric acid. Scintillation fluid was added and the
radioactivity measured in a Packard counter. Blank values
were subtracted and activities calculated as pmoles of phos-
phate incorporated during the 30-min incubation. The activ-
ities were expressed in % of the maximal activity, i.e., in the
absence of inhibitors. Controls were performed with appro-
priate dilutions of DMSO.
CDK1/cyclin B (M phase starfish oocytes, native), CDK2/
cyclin E (human, recombinant, from A. Echalier), and
CDK5/p25 (human, recombinant, expressed in E. coli) [51]
were assayed in Buffer A (supplemented extemporaneously
with 0.15 mg BSA/mL, except for CDK2) with 25 μg of
histone H1.
DYRK1A (rat, recombinant, expressed in E. coli as
GST fusion protein, provided by Dr. W. Becker), DYRK1A
(human, recombinant, expressed in E. coli as GST fusion
proteins), DYRK4 (human, recombinant, expressed in insect
cells), CLK1, 2, 3, and 4 (mouse, recombinant, expressed in
E. coli as GST fusion proteins) was assayed as described for
CDK1/cyclin B with 1 μg of RS peptide (GRSRSRSRSRSR)
as a substrate. Native DYRK1A was purified from rat brain,
taking advantage of the natural poly-histidine sequence
located in the C-terminal domain of DYRK1A, by affin-
ity chromatography on cobalt–sepharose beads (Clontech).
Briefly, after a 30-min preclearing incubation at 4 ◦C with
sepharose beads, rat brain lysates were incubated with cobalt-
sepharose beads (400 μg total proteins/20 μL beads). Kinase
activity of native DYRK1A was directly assessed on the
beads in buffer A (+0.5 mg BSA/mL) using the Woodtide
substrate (KKISGRLSPIMTEQ).
GSK-3α/β (porcine brain, native, affinity purified on
axin–sepharose beads), GSK-3α and GSK3β (human, recom-
binant, expressed in insect cells) and PfGSK-3 (Plasmodium
falciparum, recombinant, expressed in E. coli) were assayed
123
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Mol Divers (2014) 18:375–388 387
as described for CDK1/cyclin B, but using a GSK-3 specific
substrate (GS-1: YRRAAVPPSPSLSRHSSPHQpSEDEEE,
where pS stands for phosphorylated serine) [52].
Casein kinase 1 (CK1δ/ε) (porcine brain, native) was
assayed with 0.67 μg of CKS peptide (RRKHAAIGp-
SAYSITA), a CK1 specific substrate [53].
CLK1 (mouse, recombinant, expressed in E. coli as GST
fusion proteins) was assayed in buffer A (+0.15 mg BSA/mL)
with RS peptide (GRSRSRSRSRSR) (1 μg/assay).
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